FDA to publish guidance to improve the Rx to OTC switch application process - Hogan Lovells Cadwalader
FDA to publish guidance to streamline the Rx to OTC switch application process, enhancing clarity and efficiency for manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B). should confirm how it applies to their specific situation before acting. There is a time constraint attached: N/A. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New guidance from FDA aimed at improving the application process for switching prescription drugs to over-the-counter status.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B).
What you must do
Review and adapt to the new guidance once published to ensure compliance in future Rx to OTC applications.
Deadline
N/A
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Sen. Pennycuick Legislation to Help Bring New Life-Saving Treatments and Devices to Market Quicker Passes Senate - pasenategop.com
- Committee Approves Pennycuick Measure to Modernize PA Pharmaceutical Licensing - pasenategop.com
- FDA launches PreCheck Pilot program to accelerate domestic drug manufacturing facility approvals - allsci.com
- Kratom and the Impact of 7-OH Reclassification - pharmtech.com
- FDA Overhauls Drug Establishment Registration - allsci.com